Bruce Hershatter MD
Overview
Bruce Hershatter, MD, FACR, is a board certified radiation oncologist treating patients with prostate cancer at Emory Saint Joseph's Hospital with a special emphasis on the multidisciplinary evaluation of new patients. In coordination with colleagues in urology, he provides a complete analysis of options for prostate cancer treatment which may include the use of high dose rate afterloader brachytherapy, a customized form of radiotherapy that does not leave the patient with long-term radioactive material in the prostate.
Previously, Dr. Hershatter worked as a faculty physician at Duke University School of Medicine. He was then appointed medical director of radiation oncology at Georgia Baptist Medical Center (now Atlanta Medical Center). During his 14-year tenure at Atlanta Medical Center, he obtained American College of Radiology accreditation for the department, initiated a prostate brachytherapy program and inaugurated the use of high dose rate brachytherapy.
In 2001, Dr. Hershatter joined the radiation oncology faculty at Emory University School of Medicine, seeing patients at Crawford Long Hospital (now Emory University Hospital Midtown) and the Atlanta VA Medical Center. As Medical Director at the Atlanta VA Medical Center for over 10 years, Dr. Hershatter ran a full time clinical practice and successfully gained accreditation from the American College of Radiology for the department.
Dr. Hershatter's record of service to the specialty of radiation oncology includes more than 20 years on the board of the Georgia Radiological Society and more than 15 years as the radiation oncology representative for the Medicare Carrier Advisory Committee.
Dr. Hershatter is a fellow of the American College of Radiology. He is the Georgia representative to the Council of Affiliated Regional Radiation Oncology Societies and he has served on the Radiation Therapy Services Technical Advisory Committee of the Georgia Division of Health Planning. He is past president of the Georgia Radiological Society. He is a member of the House of Delegates of the Medical Association of Georgia. He serves on the council of the American College of Radiology and on the Associate Admissions Committee for the Emory University School of Medicine.
Dr. Hershatter has participated in numerous research studies and clinical protocols, including enrolling patients in and serving as principal investigator on protocols for NRG Oncology.
Dr. Hershatter graduated magna cum laude from Drew University with a degree in chemistry. He earned his MD from Tulane University. He completed his internship and residency in radiation oncology at Duke University where he also served as chief resident.
Education
Degrees
- MD from Tulane University School of Medicine
- BA from Drew University
Research
Publications
-
Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.
Cancer Volume: 131 Page(s): e35795
03/15/2025 Authors: Sebastian NT; Patil D; Patel PR; Jani AB; Hershatter BW; Dhere VR; Godette KD; Lorentz CA; Weiss AD; Joshi SS -
Impact of Rectal Spacer on Toxicity Reduction in Men Treated With Proton Versus Photon Therapy.
Int J Part Ther Volume: 13 Page(s): 100111
09/01/2024 Authors: Dhere VR; Goyal S; Zhou J; Sebastian NT; Patel AB; Hanasoge S; Patel PR; Shelton J; Godette KD; Hershatter BW -
Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy.
J Contemp Brachytherapy Volume: 16 Page(s): 268 - 272
08/01/2024 Authors: Sebastian NT; Goyal S; Liu Y; Dhere V; Jani AB; Hershatter B; Patel PR; Shelton JW; Hanasoge S; Godette KD -
Biochemical Relapse-Free Survival in Postprostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed-Only Radiation: Post Hoc Analysis of a Prospective Randomized Trial.
Volume: 14 Page(s): e492 - e499
01/01/2024 Authors: Dhere VR; Schuster DM; Goyal S; Schreibmann E; Hershatter BW; Patel SA; Shelton JW; Hanasoge S; Patel PR; Sebastian NT -
Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.
JAMA Netw Open Volume: 6 Page(s): e2327637
08/01/2023 Authors: Sebastian N; Goyal S; Liu Y; Janopaul-Naylor JR; Patel PR; Dhere VR; Hanasoge S; Shelton JW; Godette KD; Jani AB -
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
J Clin Oncol Volume: 41 Page(s): 3217 - 3224
06/10/2023 Authors: Movsas B; Rodgers JP; Elshaikh MA; Martinez AA; Morton GC; Krauss DJ; Yan D; Citrin DE; Hershatter BW; Michalski JM -
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
J Clin Oncol Volume: 41 Page(s): 3203 - 3216
06/10/2023 Authors: Krauss DJ; Karrison T; Martinez AA; Morton G; Yan D; Bruner DW; Movsas B; Elshaikh M; Citrin D; Hershatter B -
Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial.
J Nucl Med Volume: 64 Page(s): 586 - 591
04/01/2023 Authors: Lawal IO; Jani AB; Adediran OA; Goyal S; Abiodun-Ojo OA; Dhere VR; Marcus CV; Joshi SS; Master VA; Patel PR -
Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy.
Clin Nucl Med Volume: 48 Page(s): e153 - e159
04/01/2023 Authors: Lawal IO; Marcus C; Schuster DM; Goyal S; Adediran OA; Dhere VR; Joshi SS; Abiodun-Ojo OA; Master VA; Patel PR -
Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (18F) Positron Emission Tomography/Computed Tomography-Guided Postprostatectomy Radiation Therapy for Prostate Cancer: Volumetric and Patient-Reported Analyses of Toxic Effects.
Int J Radiat Oncol Biol Phys Volume: 113 Page(s): 1003 - 1014
08/01/2022 Authors: Dhere VR; Schuster DM; Goyal S; Schreibmann E; Hershatter BW; Rossi PJ; Shelton JW; Patel PR; Jani AB